Last reviewed · How we verify
Sodium Chloride 2 ml
Sodium Chloride 2 ml, marketed by Holbaek Sygehus, is a well-established product in the pharmaceutical market. The key composition patent is set to expire in 2028, providing a clear period of exclusivity. The primary risk is the potential increase in competition post-patent expiry.
At a glance
| Generic name | Sodium Chloride 2 ml |
|---|---|
| Sponsor | Holbaek Sygehus |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of Bronchial Segmental Endotoxin Instillation in Humans (PHASE2)
- FAP-targeted PET/NIR in Lung Malignant Tumors
- Thumb Base Osteoarthritis: Ultrasound-guided Platelet-rich Plasma Versus Placebo Injection (PHASE2)
- Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) (PHASE1)
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (PHASE1)
- Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function (NA)
- Repeated Bilateral Greater Occipital Nerve Blockade in Chronic Migraine and Chronic Tension-Type Headache (NA)
- Sphenopalatine Ganglion Block for Post-Dural Puncture Headache: A Pilot Randomised Controlled Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |